Next-generation sequencing to guide clinical trials

Clinical Cancer Research

Volumn 21, Issue 20, 2015, Pages 4536-4544

  Siu, Lillian L ^a   Conley, Barbara A ^b   Boerner, Scott ^c   LoRusso, Patricia M ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b NATIONAL CANCER INSTITUTE   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DNA SEQUENCE; DRUG TARGETING; GENE DOSAGE; GENE FREQUENCY; GENE MUTATION; GENETIC HETEROGENEITY; GENOTYPING TECHNIQUE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NEXT GENERATION SEQUENCING; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; GENETICS; HIGH THROUGHPUT SEQUENCING; MEDICAL RESEARCH; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS;

EID: 84945568707     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3215     Document Type: Article

References (37)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009;458:719-24.
2. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologicmalignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
3. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, et al. Molecular profiling of patients with colorectal cancer andmatched targeted therapy in phase I clinical trials. Mol Cancer Ther 2012;11:2062-71.
4. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013;501:355-64.
5. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013;12:358-69.
6. Andre F, Nowak F, Arnedos M, Lacroix L, Viens P, Calvo F. Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. Clin Cancer Res 2012;18:1555-60.
7. Lindsay CR, Shaw E, Walker I, Johnson PW. Lessons for molecular diagnostics in oncology from the Cancer Research UK Stratified Medicine Programme. Expert Rev Mol Diagn 2015;15:287-9.
8. Foundation Medicine [homepage on the Internet]. Cambridge,MA: Foundation Medicine; c2015 [cited 2015 Mar 1]. Available from: http://www. foundationmedicine.com/.
9. Caris Life Sciences [homepage on the Internet]. Irving, TX: Caris Life Sciences; c2015 [cited 2015 Mar 1]. Available from: http://www.carislifesciences. com/.
10. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
11. Liang YH, Lin YL, Liau JY, Tsai JH, Liang JT, Lin BR, et al. Cetuximab might be detrimental to metastatic colorectal cancer patients with KRAS codon 12 mutations. Anticancer Res 2015;35:4207-14.
12. Spencer DH, Sehn JK, Abel HJ, Watson MA, Pfeifer JD, Duncavage EJ. Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn 2013; 15:623-33.
13. Kopetz S, Overman MJ, Chen K, Lucio-Eterovic AK, Kee BK, Fogelman DR, et al. Mutation and copy number discordance in primary versusmetastatic colorectal cancer (mCRC). J Clin Oncol 32:5s, 2014 (suppl; abstr 3509).
14. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86.
15. dbSNP: Short Genetic Variations [database on the Internet]. Bethesda, MD: National Center for Biotechnology Information [cited 2015 Mar 3]. Available from: http://www.ncbi.nlm.nih.gov/SNP/.
16. 1000 Genomes: A Deep Catalog of Human Genetic Variation [database on the Internet]. Hinxton, UK: European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI); c2008-2012 [cited 2015 March 3]. Available from: http://www.1000genomes.org/.
17. Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014;15: 267-74.
18. Bates SE, Berry DA, Balasubramaniam S, Bailey S, LoRusso PM, Rubin EH. Advancing clinical trials to streamline drug development. Clin Cancer Res 2015;21:4527-35.
19. Theoret MR, Pai-Scherf LH, Chuk MK, Prowell TM, Balasubramaniam S, Kim T, et al. Expansion cohorts in first-in-human solid tumor oncology trials. Clin Cancer Res 2015;21:4545-51.
20. Seruga B, Ocana A, Amir E, Tannock IF. Failures in phase III: causes and consequences. Clin Cancer Res 2015;21:4552-60.
21. Stewart DJ, Batist G, Kantarjian HM, Bradford J-P, Schiller JH, Kurzrock R. The urgent need for clinical research reform to permit faster, less expensive access to new therapies for lethal diseases. Clin Cancer Res 2015;21: 4561-8.
22. Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol 2015;33:975-7.
23. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat Med 2013;19:655.
24. Kummar S, Williams PM, Lih CJ, Polley EC, Chen AP, Rubinstein LV, et al. Application of molecular profiling in clinical trials for advanced metastatic cancers. J Natl Cancer Inst 2015;107:djv003.
25. Heinrich MC, Joensuu H, Demetri GD, Corless CL, Apperley J, Fletcher JA, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res 2008;14: 2717-25.
26. Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 2013;105:1677-83.
27. Freidlin B, McShane LM, Polley MY, Korn EL. Randomized phase II trial designs with biomarkers. J Clin Oncol 2012;30:3304-9.
28. LUNG-MAP [homepage on the Internet]. c2015 [cited 2015 Mar 1]. Available from: www.lung-map.org.
29. Steuer CE, Papadimitrakopoulou V, Herbst RS, Redman MW, Hirsch FR, Mack PC, et al. Innovative clinical trials: the LUNG-MAP study. Clin Pharmacol Ther 2015;97:488-91.
30. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013;15:565-74.
31. Catenacci DV, Amico AL, Nielsen SM, Geynisman DM, Rambo B, Carey GB, et al. Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer 2015;136:1559-67.
32. Conley BA, Doroshow JH. Molecular analysis for therapy choice: NCI MATCH. Semin Oncol 2014;41:297-9.
33. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015; 348:124-8.
34. Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, Iyer A, et al. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. Cell 2014;159: 402-14.
35. Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med 2015;12:e1001789.
36. Hiley CT, Swanton C. Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clin Med 2014;14 Suppl 6:s33-7.
37. Kaplan R, Maughan T, Crook A, Fisher D, Wilson R, Brown L, et al. Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol 2013;31:4562-8.